Despite some clear evidence that TIM-3 may play a key immunoregulatory role that promotes glioblastoma development and progression, currently, clinical evaluation of anti-TIM-3 agents in the glioblastoma setting is limited. This evidence concerns the gene HAVCR2 and glioblastoma.